Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced…
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of…
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for authorizing medicinal products in France, has granted “accès compassionnel” (compassionate access) to AMX0035…
Stevanato Group Announces Voting Results from its Extraordinary General Meeting Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that the resolution…
Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health Elligo Health Research®, the largest healthcare-enabling research organization, today announced it is expanding its Study Marketplace platform with Syneos Health, a leading fully integrated biopharmaceutical solutions organization built to accelerate…
Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific Lokavant, the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co.…
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to…
Advent International and Warburg Pincus Complete Acquisition of Baxter’s BioPharma Solutions Business Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced the completion of their previously…
Bausch + Lomb Completes Acquisition of XIIDRA Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a…
Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine Cimeio Therapeutics, a biotechnology company that is reimagining immunotherapy with its Shielded Cell and Immunotherapy (SCIP®) platform, along with Prof. Lukas Jeker’s team at the Department…
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart…
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer Bristol Myers Squibb today announced the Phase 3 CheckMate -77T trial met its primary endpoint of…